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DERIVING CHEMOSENSITIVITY FROM CELL LINES:
FORENSIC BIOINFORMATICS AND REPRODUCIBLE
RESEARCH IN HIGH-THROUGHPUT BIOLOGY
By Keith A. Baggerly1 and Kevin R. Coombes2
University of Texas
High-throughput biological assays such as microarrays let us ask
very detailed questions about how diseases operate, and promise to
let us personalize therapy. Data processing, however, is often not de-
scribed well enough to allow for exact reproduction of the results,
leading to exercises in “forensic bioinformatics” where aspects of raw
data and reported results are used to infer what methods must have
been employed. Unfortunately, poor documentation can shift from an
inconvenience to an active danger when it obscures not just methods
but errors. In this report we examine several related papers purport-
ing to use microarray-based signatures of drug sensitivity derived
from cell lines to predict patient response. Patients in clinical trials
are currently being allocated to treatment arms on the basis of these
results. However, we show in five case studies that the results incor-
porate several simple errors that may be putting patients at risk. One
theme that emerges is that the most common errors are simple (e.g.,
row or column offsets); conversely, it is our experience that the most
simple errors are common. We then discuss steps we are taking to
avoid such errors in our own investigations.
1. Background.
1.1. General. High-throughput biological assays such as microarrays let
us ask very detailed questions about how diseases operate, and promise to let
us personalize therapy. For example, if we know a priori that only about 70%
of a group of cancer patients will respond to standard front-line therapy (as
is the case with ovarian cancer), then an array-based test indicating whether
a given patient is likely to respond would have great clinical utility.
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Data processing in high-throughput studies, however, is often not de-
scribed well enough to allow for exact reproduction of the results. While
various groups have made efforts to construct tools or compendia that should
make such reproducibility easier [e.g., Leisch (2002), Ruschhaupt et al. (2004),
Gentleman (2005), Gentleman and Temple Lang (2007), Li (2008)], a recent
survey [Ioannidis et al. (2009)] of 18 quantitative papers published in Nature
Genetics in the past two years found reproducibility was not achievable even
in principle for 10. The time period is relevant, as the journal was then requir-
ing that all raw data be deposited in public repositories so reproducibility
would be easier. In some cases, more extensive exercises in “forensic bioin-
formatics” [e.g., Stivers et al. (2003), Baggerly, Morris and Coombes (2004),
Baggerly et al. (2004, 2005), Coombes, Wang and Baggerly (2007)] can use
aspects of raw data and reported results to infer the methods that must
have been employed, but these are time-consuming.
Unfortunately, poor documentation and irreproducibility can shift from
an inconvenience to an active danger when it obscures not just methods but
errors. This can lead to scenarios where well-meaning investigators argue in
good faith for treating patients with apparently promising drugs that are
in fact ineffective or even contraindicated. In some ways, this problem is
qualitatively worse for high-throughput assays than it is for simple tests,
because the sheer magnitude of the data confounds both our ability to spot
simple errors and our intuition about how certain tests “should” behave.
For several single-marker assays, investigators may have a well-developed
intuition that high values indicate a poor prognosis, but 50-gene signatures
require faith that the assembly code has been applied correctly.
In this report we try to illustrate the potential severity of the problem by
examining several related papers purporting to use microarray-based signa-
tures of drug sensitivity derived from cell lines to predict patient response.
Patients in clinical trials are currently being allocated to treatment arms on
the basis of these results. However, we show in five case studies that the re-
sults incorporate several simple errors that may be putting patients at risk.
The complete code and documentation underlying our results are available
as supplementary material (see the Appendix). We then discuss steps we are
taking to avoid such errors in our own investigations.
1.2. Chemosensitivity and cell lines. While many microarray studies have
clarified aspects of basic cancer biology, there is a definite push to make our
studies more “translational” in that our bench or in silico results should
be likely to translate into changes in patient care in short order. To that
end, studies identifying new targets for drug development are of less import
than studies guiding how we use the drugs available to us now. In short, we
would like to know whether a given patient is likely to be sensitive (aka be
a responder) to a given agent.
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In this context, we briefly consider how the activity of new chemother-
apeutics is assessed. Shortly after cytotoxic chemotherapy was introduced
for the treatment of leukemia, the U.S. government established the Cancer
Chemotherapy National Service Center (CCNSC) in part to help test new
agents. Drugs were submitted, assigned an NSC number, and used to treat
leukemic mice to see if they produced improvement. Both the agency and
the method of testing have changed over time. The CCNSC was absorbed
into the Developmental Therapeutics Program (DTP), but every new drug
submitted is still assigned an NSC number. Tests shifted first from leukemic
mice to immunologically compromised (nude) mice onto which various types
of human tumors were grafted, and thence to a standard panel of cell lines
(the NCI60) derived from 9 types of human tumors. Sensitivity is assessed
in cell lines through dilution assays. Six samples (aliquots) of a given cell
line are put into separate wells, a starting dose is applied to well 1, one
tenth that dose is applied to well 2, and so on through well 5; well 6 is left
untreated. After a fixed period, the amount of growth seen in the treated
wells is assessed relative to growth in the untreated well. Summary measures
reported are the estimated doses required to achieve 50% growth inhibition
(GI50 or IC50), total growth inhibition (TGI) or not only growth inhibition
but 50% lethality of the starting cells (LC50). The important thing about
this approach is that data on activity against the NCI60 panel is publicly
available for every chemotherapeutic now in use, so a method of constructing
sensitivity signatures from this panel would have extremely broad applica-
bility.
1.3. Initial claims. In late 2006, Potti et al. (2006) introduced a method
for combining microarray profiles of the NCI60 with drug sensitivity data
to derive “signatures” of sensitivity to specific drugs, which they then used
to predict patient response. In theory, the approach is straightforward:
• Using drug sensitivity data for a panel of cell lines, choose those that are
most sensitive and most resistant to a drug.
• Using array profiles of the chosen cell lines, select the most differentially
expressed genes.
• Using the selected genes, build a model that takes an array profile and
returns a classification, and use this model to predict patient response.
They reported success using this approach with several common chemother-
apeutic agents, specifically docetaxel, doxorubicin (adriamycin), paclitaxel
(taxol), 5-fluorouracil (fluorouracil, FU, or 5-FU), cyclophosphamide (cy-
toxan), etoposide and topotecan. They also reported some initial success at
predicting response to combination therapies. Unsurprisingly, these results
generated a lot of attention. The approach was named one of “The Top 6
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Genetics Stories of 2006” [Discover (2007)], is the subject of U.S. Patent Ap-
plication 20090105167, “Predicting responsiveness to cancer therapeutics”
[Potti, Nevins and Lancaster (2009)], and had been cited in 212 papers by
August 2009 (Google Scholar).
1.4. Initial questions and response. Several groups at MD Anderson were
among those excited, and we examined the approach in order to help our in-
vestigators use this. However, as documented in Coombes, Wang and Baggerly
(2007), when we independently reanalyzed the raw data, we noted a number
of simple errors affecting the conclusions. Taking doxorubicin as an exam-
ple, we noted that Potti et al. (2006) predicted response in a test set cohort
involving samples from 122 patients; 23 patients were reportedly sensitive to
doxorubicin and 99 resistant [Potti et al. (2006), Figure 2C]. However, this
data was said to arise from an “independent dataset of samples cultured from
adriamycin-treated individuals (GEO accession nos. GSE650 and GSE651).”
These Gene Expression Omnibus (GEO) data sets, which derive from a study
on acute lymphocytic leukemia (ALL) by Holleman et al. (2004), give gene
profiles for samples from 94 patients sensitive to daunorubicin (in the same
chemical family as doxorubicin) and 28 resistant. While the total number
of patients (122) is constant, the proportions (23 : 99 and 94 : 28) are al-
most inverted, which led us to suggest that the sensitive/resistant labels
might have been reversed. Label reversal implies that an “accurate” signa-
ture would preferentially suggest doxorubicin for patients who would not
benefit.
In reply, Potti and Nevins (2007) disagree, claiming that their approach is
“reproducible and robust.” In support of this claim, they comment on “the
acute lymphocytic leukemia dataset in which the labels are accurate—full
details are provided on our web page.” They note having gotten the ap-
proach to work again more recently [e.g., Hsu et al. (2007), Bonnefoi et al.
(2007)], and conclude that the Coombes, Wang and Baggerly (2007) analy-
sis is flawed.
1.5. Subsequent progress. Progress since 2006 appears substantial.
Hsu et al. (2007) used the same approach to develop signatures of response
to cisplatin and pemetrexed, extending the range of treatments that could
be compared. In examining these signatures, they identified specific compo-
nents strongly suggesting biological plausibility, noting that
“The cisplatin sensitivity predictor includes DNA repair genes such as ERCC1
and ERCC4, among others, that had altered expression in the list of cisplatin
sensitivity predictor genes. Interestingly, one previously described mechanism
of resistance to cisplatin therapy results from the increased capacity of cancer
cells to repair DNA damage incurred, by activation of DNA repair genes.”
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Clinical trial TOP0602 (NCT00509366), now underway, will “assign subjects
to either pemetrexed/gemcitabine or cisplatin/gemcitabine therapy using
a genomic based platinum predictor to determine chemotherapy sensitivity
and predict response to chemotherapy for first-line therapy in advanced non-
small cell lung cancer.” [Clinical Trial NCT00509366 (2009)].
Later, Bonnefoi et al. (2007) provided a “validation” of the combination
approach, using it to predict patient response to two alternative therapies:
taxotere followed by epirubicin and taxotere (TET), and fluorouracil, epiru-
bicin and cyclophosphamide (FEC). This report is a substudy of the Eu-
ropean clinical trial EORTC 10994/BIG 00-01, in which breast cancer pa-
tients are randomized to receive either TET or FEC. Based on their results,
Bonnefoi et al. (2007) suggest that using their predictions might have im-
proved response rates in the target population from 44% to 70%, a huge
benefit.
The most recent application was when Augustine et al. (2009) used the
approach to construct a signature for temozolomide. The procedure now
appears fairly standardized:
“A signature of gene expression that correlated with resistance to temozolo-
mide was derived from the NCI-60 panel of cancer cell lines (ref. 17; see also
Supplementary data). From this panel of 60 cell lines, a smaller subset of 15
was selected that represented two extremes of sensitivity to temozolomide;
nine of these cell lines were classified as resistant and six as sensitive. Us-
ing the gene expression profiles of these cell lines, we identified 45 genes that
showed significantly different expression patterns between the resistant and
sensitive cell lines and thus provided a temozolomide sensitivity gene signa-
ture (see Supplementary Table S4). The color-coded heatmap of expression of
the 45 temozolomide genes across these 15 cell lines (Fig. 4A) shows 8 genes
(red) that were more highly expressed in the resistant than in the sensitive
cell lines, whereas 37 genes (blue) were more highly expressed in the sensitive
than in the resistant cell lines.”
In sum, the procedure apparently gives good predictions in independent
test sets, has some biological plausibility, appears to be giving stable results
over years of application, and is consequently guiding treatment.
1.6. Cases we examine here. While there are other studies, we examine
four of the cases listed above in more detail. We chose to examine doxoru-
bicin because it is the drug for which we have the most information about
specific predictions. We chose to examine cisplatin and pemetrexed both be-
cause the cisplatin signature contains specific genes that have been linked to
drug resistance (e.g., ERCC1 and ERCC4) and because these signatures are
guiding therapy now. We chose to examine the combination validation be-
cause most cancer patients get several drugs, not one. We chose to examine
temozolomide because it is the most recent application we have seen.
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Table 1
Locations of data used in our analyses. Excel files were converted to csv files for loading
into R.
All data not posted elsewhere is available from our web site
Data sources
Potti et al. (2006) web site, accessed April 4, 2009
http://data.genome.duke.edu/NatureMedicine.php
Adria ALL data1 n95.doc GEO ids and Sens/Res calls for 95 samples
Celllines in each predictor1.xls Sens/Res cell lines for each drug
ChemopredictorsParameters.xls Binreg parameter settings for 11 drugs
DescriptionOfPredictorGeneration.doc Cell line selection for docetaxel
GeneLists.zip Probesets splitting Sens/Res cell lines
MDACC data.zip TFAC Individual and combo predictions
ParametersForImplementingSoftware.xls Binreg parameter settings for 7 drugs
Binreg.zip Metagene prediction software
Potti et al. (2006) web site, November 6, 2007, no longer posted
Adria ALL.txt Numbers, Sens/Res labels for 144 samples,
22 training cell lines, 122 testing samples
Hsu et al. (2007) journal web site, April 4, 2009
10593 Supplementary Information.doc Supplementary Methods
10593 Supplementary Table 1.doc Cisplatin gene list
10593 Supplementary Table 2.doc Pemetrexed gene list
Figure 1 Cisplatin and pemetrexed heatmaps
Gene Expression Omnibus (GEO), April 4, 2009
GSE649 Holleman et al. (2004) vincristine Res
GSE650 Holleman et al. (2004) daunorubicin Sens
GSE651 Holleman et al. (2004) daunorubicin Res
GSE2351 Lugthart et al. (2005) multi-drug Res
GSE6861 Bonnefoi et al. (2007) array CEL files
The goals of our reanalyses differ slightly by study, partially reflecting
differences in the types of data available. For doxorubicin, we tried to con-
firm the accuracy of the test set predictions. For cisplatin and pemetrexed,
we tried to confirm the identities of the genes comprising the signature.
For combination therapy, we tried to clarify the combination rules and val-
idate predictions for the single best performing drug (cyclophosphamide).
For temozolomide, we tried to confirm the association between the drug
named and the results provided.
Finally, we provide a broader overview by graphically summarizing the
cell lines designated sensitive and resistant to various drugs.
Data sources are listed in Table 1.
2. Case study 1: Doxorubicin. We begin by examining the data for
doxorubicin, where the most test set prediction details are available.
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Table 1
(Continued)
Data sources
Holleman et al. (2004) web site, April 4, 2009 http://www.stjuderesearch.org/data/ALL4/
key.xls List of Holleman et al. (2004) files at GEO
Drug sens., April 4, 2009, http://dtp.nci.nih.gov/docs/cancer/cancer_data.html
GI50 AUG08.BIN GI50 values, all drugs, August 2008 release
LC50 AUG08.BIN LC50 values, all drugs, August 2008 release
TGI AUG08.BIN TGI values, all drugs, August 2008 release
NCI60 array data, April 4, 2009, http://dtp.nci.nih.gov/mtargets/download.html
WEB HOOKS NOV GC ALL.ZIP MAS5.0 quantifications, U95A arrays
Augustine et al. (2009) journal web site, April 4, 2009
Figure 4 Temozolomide heatmap
1.pdf Gene list and metagene scores
Bonnefoi et al. (2007) journal web site, April 4, 2009
mmc1.pdf Webappendix with algorithm description
mmc2.pdf Webfigure of individual drug ROC curves
mmc3.pdf Webpanel listing cell lines used by drug
mmc4.pdf Webtable 1 listing X3p Probesets by drug
mmc5.pdf Webtable 2 Clinical data for samples used
Bonnefoi et al. (2007) files obtained from contact for GSE 6861. Not posted.
dataBonnefoiPaper.txt Drug and combination scores
HB131.CEL CEL file missing from GEO
This data was discussed by Potti et al. (2006), questioned by
Coombes, Wang and Baggerly (2007), reaffirmed by Potti and Nevins (2007),
and revisited by Potti et al. (2008) as discussed below. In terms of documen-
tation and reproducibility, our goal here is to confirm the test set prediction
accuracy.
2.1. Test data responder/nonresponder counts match those reported. We
first acquired the raw doxorubicin (adriamycin) data (Adria ALL.txt) posted
by Potti and Nevins (2007). This file contains 144 data columns: 22 for
the cell lines used as training data, and 122 for test data samples. Sample
columns are not named, but sensitive/resistant status is indicated for each.
A side comment notes that “Validation data is from GSE4698, GSE649,
GSE650, GSE651, and others.” We then checked label counts for the test
data: 99 columns are labeled NR (nonresponders) and 23 Resp (responders),
matching those reported by Potti et al. (2006).
2.2. Training data sensitive/resistant labels are reversed. We next tried
to identify the cell lines used in the training set by matching the numbers
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reported to those in the table of NCI60 quantifications (see Table 1), fo-
cusing on those for the 22 cell lines used to produce the initially reported
heatmap signature [Potti et al. (2006), Figure 2A]. The posted numbers have
been transformed relative to the MAS5 quantifications used earlier. After
some experimentation, we found that the data were log-transformed, the
values for each row (gene) were centered and scaled to have mean zero and
unit variance (separately for training and test data), exponentiated to undo
the log-transform, and rounded to two decimal places. In order to match the
numbers more precisely, we transformed the NCI60 quantifications the same
way. The initial training data matrix for doxorubicin has 12558 rows (the
12625 Affymetrix U95Av2 probesets less 67 controls), but Adria ALL.txt
has 8958. This is due to the fact that the test data come from U133Av2
arrays, and the mapping across platforms matched probes based on unique
LocusLink IDs. Since the rows are not labeled, we simply tried checking all
row-by-row correlations between Adria ALL.txt and the transformed NCI60
data pertaining to the 22 cell lines in the initial heatmap by brute force. We
identified perfect matches for all 8958, establishing that the 10 cell lines
labeled “Resistant” are SF-539, SNB-75, MDA-MB-435, NCI-H23, M14,
MALME-3M, SK-MEL-2, SK-MEL-28, SK-MEL-5 and UACC-62, and the
12 cell lines labeled “Sensitive” are NCI/ADR-RES, HCT-15, HT29, EKVX,
NCI-H322M, IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, SK-
OV-3 and CAKI-1. These lines (in this order) do produce the heatmap shown
in Figure 2A of Potti et al. (2006), and the sensitive/resistant orientation is
consistent with their Supplementary Figure 2, which notes that heatmaps
for each predictor have “resistant lines on the left, and sensitive on the
right.” However, the labels are reversed relative to those now supplied on
the Potti et al. (2006) web site in “Cell lines used in each chemo predictor.”
Since the listing above places NCI/ADR-RES (“adriamycin resistant”) in
the sensitive group, the training labels in Adria ALL.txt are reversed.
2.3. Heatmaps show sample duplication in the test data [Figure 1( a)]. In
order to see how well the doxorubicin signature separates test set respon-
ders from nonresponders, we extracted the test set expression values for
the probesets in the doxorubicin signature (using the identifications from
the previous step), log-transformed them, and clustered the samples [Fig-
ure 1(a)]. We did not see clear separation of responders from nonresponders,
but we did see “blocks” of samples having exactly the same profiles: some
test data samples were reused. Two such blocks are marked.
2.4. Only 84/122 test samples are distinct; some samples are labeled both
sensitive and resistant [Figure 1(b)]. In order to get a more precise idea
of the extent of the duplication, we examined all pairwise sample correla-
tions for Adria ALL.txt. Figure 1(b) highlights pairs with correlations above
CELL LINES, CHEMO AND REPRODUCIBILITY 9
0.9999 (duplicates). Circles indicate duplicates with consistent labels; trian-
gles indicate duplicates where the same sample was labeled sensitive in one
column and resistant in the other. Only 84 of the 122 test samples are dis-
tinct: 60 are present once, 14 twice, 6 three times, and 4 four times. Columns
32 (dashed line), 66, 89 and 117 in Adria ALL.txt are all the same, but they
are labeled Sensitive, Resistant, Resistant and Resistant respectively [this is
the set of samples marked at the right in Figure 1(a)].
2.5. Communication with the journal elicited a second correction. This
correction [Potti et al. (2008)] notes that
“of the 122 samples assayed for sensitivity to daunorubicin for which the au-
thors applied a predictor of adriamycin sensitivity, 27 samples were replicated
(a) (b)
Fig. 1. ( a) Heatmap of test samples from Adria ALL.txt, using expression values for
genes in the doxorubicin signature. Samples are labeled as “NR” (red) or “Resp” (blue).
Responders and nonresponders show no clear separation. However, the clustering shows
that some samples are tied (horizontal segments near the dendrogram base). Lines border
one group of tied samples at left, and another group of tied samples at right; there are
others. Colors for the tied block at right show Resp once and NR three times. (b) Dotplot
identifying identical columns in the full Adria ALL.txt matrix. There are no unwanted ties
in the training data (lower left corner, separated by solid lines). In the test data (upper
right), however, there are tied pairs labeled both consistently (circles) and inconsistently
(triangles). One column from the right-hand block from ( a) is marked with a dashed line;
sample 32 (main diagonal) is labeled “Resp,” but samples 66, 89, and 117 are labeled
“NR” (triangles).
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owing to the fact that the same samples were included in several separate se-
ries files in the Gene Expression Omnibus generated in 2004 and 2005, which
were the source of the data provided for the study.”
This correction also notes that data were acquired from two other sources
in addition to GSE650 and GSE651: GSE2351 [Lugthart et al. (2005)] and
GSE649 [Holleman et al. (2004)].
2.6. The new data also has duplications and samples listed both ways (Ta-
ble 2). At the time of the Potti et al. (2008) correction, Adria ALL.txt was
removed from the web site and replaced with Adria ALL data1 n95.doc.
Adria ALL data1 n95.doc gives no quantifications, but rather lists 95 GEO
array ids and gives a sensitive/resistant label for each. The first twenty data
rows from this file are shown in Table 2. Rows 3/4, 9/10 and 17/18 list the
same samples. Further, the status labels in rows 17/18 conflict. Looking at
all the names shows that only 80 are distinct: 15 are duplicated, and 6 of
these show the same sample labeled both RES and SEN.
2.7. At least 3/8 of the test data is incorrectly labeled resistant (Table 3).
Given the test sample ids, it is also possible to compare the classifications
Potti et al. (2008) assigned (not predicted, but rather what they are trying
to predict) to the 80 unique samples with the classifications assigned using
the rules from Holleman et al. (2004), the source of the test data (Table 3).
Between 29 and 35 samples Holleman et al. (2004) would call sensitive are
classed by Potti et al. (2008) as resistant, with the uncertainty due to dupli-
cate samples with inconsistent calls. There are 10 samples Holleman et al.
(2004) would call “intermediate” that are classed by Potti et al. (2008) as
resistant. All of the changes add to the number of “resistant” cases. This
Table 2
The first 20 rows of Adria ALL data1 n95.doc. Visual examination shows rows 3/4, 9/10
and 17/18 (marked) are the same. Rows 17/18 label the same sample both ways
Row Sample ID Response Row Sample ID Response
1 GSM44303 RES 11 GSM9694 RES
2 GSM44304 RES 12 GSM9695 RES
3 GSM9653* RES 13 GSM9696 RES
4 GSM9653* RES 14 GSM9698 RES
5 GSM9654 RES 15 GSM9699 SEN
6 GSM9655 RES 16 GSM9701 RES
7 GSM9656 RES 17 GSM9708* RES
8 GSM9657 RES 18 GSM9708* SEN
9 GSM9658* SEN 19 GSM9709 RES
10 GSM9658* SEN 20 GSM9711 RES
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Table 3
Joint classifications of the 80 distinct samples in Adria ALL data1 n95.doc. Holleman
et al. (2004) class most samples as sensitive to daunorubicin; Potti et al. (2006) class
most as resistant. Adria ALL data1 n95.doc has 95 rows with 15 duplicates; 6 duplicates
are labeled inconsistently and are classed as “Both”
Holleman et al. (2004) classifications
Sensitive Intermediate Resistant
Potti et al. (2006) Sensitive 13 0 0 13
classifications Resistant 29 10 22 61
Both 6 0 0 6
48 10 22
shift is not achievable by simply moving the LC50 cutoff to redefine the
sensitive/resistant boundary, as LC50 values for “sensitive” and “resistant”
samples overlap.
2.8. Summary. Poor documentation hid both sensitive/resistant label
reversal, and the incorrect use of duplicate (and in some cases mislabeled)
samples. These problems were hidden well enough to survive two explicit
corrections. Code and documentation for this case study are given in Sup-
plementary File 1 [Baggerly and Coombes (2009a)].
3. Case study 2: Cisplatin and pemetrexed. We next examined data for
cisplatin and pemetrexed, where (a) specific genes in the cisplatin signature
(ERCC1, ERCC4) were identified as providing a plausible rationale for its
effectiveness and (b) the signatures are guiding therapy. Most signatures we
discuss (including that for pemetrexed) are assembled from the NCI60, but
Hsu et al. (2007) comment that
“The collection of data in the NCI-60 data occasionally does not represent a
significant diversity in resistant and sensitive cell lines to any given drug. Thus,
if a drug screening experiment did not result in widely variable GI50/IC50
and/or LC50 data, the generation of a genomic predictor is not possible using
our methods, as in the case of cisplatin.”
Thus, Hsu et al. (2007) assembled the cisplatin signature from a panel of 30
cell lines profiled by Gyo¨rffy et al. (2006). Gyo¨rffy et al. supply both U133A
array quantifications and classifications of which cell lines were sensitive, in-
termediate or resistant in their response to various drugs, including cisplatin
(their Figure 2). In terms of documentation and reproducibility, our goal here
is to recreate the signature. We acquired the cisplatin and pemetrexed gene
lists from Hsu et al. (2007)’s Supplementary Tables 1 and 2, respectively.
We acquired the Gyo¨rffy et al. (2006) expression data from their supporting
12 K. A. BAGGERLY AND K. R. COOMBES
Table 1. We acquired the binreg Matlab scripts used for model fitting and
heatmap generation from the Potti et al. (2006) web site. As the analyses
are largely parallel, we focus on cisplatin first, turning to pemetrexed only
in the next to last subsection.
3.1. A heatmap using the cisplatin genes shows no separation of the cell
lines [Figure 2( a)]. In order to see how clearly the sensitive and resistant
cisplatin cell lines were separated, we extracted and clustered the expression
submatrix for the signature genes across all 30 cell lines [Figure 2(a)]. The
heatmap shows no clear split between sensitive and resistant cell lines.
3.2. A heatmap using offset cisplatin genes shows clear separation of the
cell lines [Figure 2(b)]. Coombes, Wang and Baggerly (2007) noted that
several of the gene lists initially reported by Potti et al. (2006) were “off-
by-one” due to an indexing error, so we also extracted and clustered the
expression submatrix for the “offset” cisplatin signature genes across all
30 cell lines, producing the heatmap shown in Figure 2(b). This offset in-
volves a single row shift: for example, quantifications from row 98 (probeset
200076 at) of the Gyo¨rffy et al. (2006) table were used instead of those from
row 97 (probeset 200075 s at). This heatmap shows a clear split between
sensitive and resistant cell lines.
3.3. Clustering correlations suggests the cell lines involved [Figure 2( c)].
Gyo¨rffy et al. (2006) list 20 and 7 lines as resistant and sensitive to cisplatin,
respectively (3 are listed as intermediate), but Hsu et al. (2007) show 9
and 6. In order to figure out which cell lines were used, we clustered the
correlations between sample columns from the expression submatrix for the
offset genes shown in Figure 2(b). This clustering, shown in Figure 2(c),
shows two clear groups of cell lines: 10 in the upper right and 7 in the lower
left. We used the sensitive and resistant labels from Gyo¨rffy et al. (2006) to
suggest which group was which (upper right is resistant). Checking the labels
assigned by Gyo¨rffy et al. (2006) shows that SKMel13 (Sensitive) and Skov3
(Intermediate) do not fit with the others of their respective groups. Omitting
these gives the following 9 “Resistant” cell lines: 257P, A375, C8161, ES2,
me43, MeWo, SKMel19, SNU423 and Sw13; and 6 “Sensitive” cell lines:
BT20, DV90, FUOV1, OAW42, OVKAR and R103. We checked this further
using a brute force “steepest ascent” method with their binreg software as
follows. Starting with our initial guess of 10 and 7 lines, we labeled each
of the 30 cell lines as resistant, sensitive or not used. We gave our guess
a score equal to the number of offset probeset ids matching the binreg
output (our starting score was 30). We then examined all 60 combinations
of cell lines that could be reached by changing the status of one cell line
from its current state to resistant, sensitive or not used, and moved to the
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Fig. 2. Images used in reconstructing the Hsu et al. (2007) heatmap for cisplatin. ( a)
Heatmap of the named cisplatin signature genes across the 30 Gyo¨rffy et al. (2006) cell
lines. There is very little structure visible. (b) Heatmap across the same cell lines using
expression values for genes obtained by “offsetting” by one row (e.g., replacing 200075 s at
with 200076 at). There is clear separating structure. ( c) Heatmap clustering pairwise sam-
ple correlations from the expression submatrix shown in (b). Red clusters (high correla-
tions) in the lower left and upper right suggest initial guesses at the lines that should be
treated as “sensitive” and “resistant” respectively. (d) Heatmap produced by binreg using
cell lines noted in the text. This is an exact match for the heatmap in Hsu et al. (2007),
confirming the cell lines and genes involved.
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combination with the highest score (36, obtained by dropping SKOV-3 from
the sensitive group), and iterating until a local maximum was reached (41,
on the second step, after dropping SKMel-13 from the resistant group).
3.4. Applying binreg perfectly reproduces the reported heatmap [Fig-
ure 2(d)]. When we apply binreg to identify the top 45 genes differen-
tiating the cell lines named above, binreg produces the heatmap shown in
Figure 2(d). This is an exact match to the cisplatin heatmap reported by
Hsu et al. (2007), confirming the cell lines used and identifying the genes
involved.
3.5. The software produces 41/45 offset genes; the others are the ones ex-
plicitly mentioned. We compared the cisplatin gene list binreg produced
for the matching heatmap with the gene list Hsu et al. (2007) reported. We
match 41 of the 45 probesets using the offset gene list. The four probesets
we do not match after offsetting (the “outliers”) are 203719 at (ERCC1),
210158 at (ERCC4), 228131 at (ERCC1) and 231971 at (FANCM, associ-
ated with DNA Repair), which Hsu et al. (2007) explicitly mention as inter-
esting components of the signature.
3.6. Two of the “outlier” genes are not on the arrays used. It is actu-
ally vacuous to say we cannot match 228131 at (ERCC1) and 231971 at
(FANCM; DNA Repair), as Gyo¨rffy et al. (2006) report no quantifications
for these probesets. Checking the U133 probeset annotation files available
from Affymetrix (http://www.affymetrix.com) shows that these probesets
are on the U133B array platform, not the U133A, so Gyo¨rffy et al. (2006)
did not measure them. [The heatmaps in Figures 2(a) and (b) only have 43
rows.]
3.7. ERCC1 and ERCC4 have been outliers before. Coombes, Wang and
Baggerly (2007) noted that several gene lists initially reported by Potti et al.
(2006) contained genes that binreg did not produce. ERCC1 and/or ERCC4
were outliers in the gene lists initially reported for docetaxel, paclitaxel and
doxorubicin as well as cisplatin. The other outliers are shown in Table 4.
3.8. Genes are offset, and sensitive/resistant labels are reversed for peme-
trexed. Having matched cisplatin, we then turned to pemetrexed. We used
the steepest ascent method described above to identify the cell lines and
genes in the pemetrexed signature. After offsetting, we are able to match all
85 genes and to perfectly match the heatmap shown. The 8 “Resistant” cell
lines are K-562, MOLT-4, HL-60(TB), MCF7, HCC-2998, HCT-116, NCI-
H460 and TK-10, and the 10 “Sensitive” cell lines are SNB-19, HS 578T,
MDA-MB-231/ATCC, MDA-MB-435, NCI-H226, M14, MALME-3M, SK-
MEL-2, SK-MEL-28 and SN12C. Unfortunately, checking the GI50 data for
pemetrexed shows that the sensitive/resistant labels are reversed.
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Table 4
“Outlier” probesets in the initially reported gene lists for Potti et al. (2006) (docetaxel,
paclitaxel, doxorubicin) and Hsu et al. (2007) (cisplatin). ERCC1 and ERCC4 are
common. Probesets for cisplatin marked with an asterisk come from the U133B array
platform, not the U133As used.
The table does not include 14 outliers in the initial signature for docetaxel that are also
found in the list reported by Chang et al. (2003) as being effective separators in the
docetaxel test set
U95Av2 PS Docetaxel Paclitaxel Doxorubicin U133A PS Cisplatin
114 r at MAPT 203719 at ERCC1
1258 s at ERCC4 ERCC4 ERCC4 210158 at ERCC4
1802 s at ERBB2 ERBB2 228131 at ERCC1*
1847 s at BCL2 231971 at FANCM*
1878 g at ERCC1 ERCC1
1909 at BCL2
1910 s at BCL2
2034 s at CDKN1B
33047 at BCL2L11 BCL2L11
36519 at ERCC1
40567 at K-ALPHA-1 K-ALPHA-1
3.9. Summary. Poor documentation hid an off-by-one indexing error af-
fecting all genes reported, the inclusion of genes from other sources, in-
cluding other arrays (the outliers), and a sensitive/resistant label rever-
sal. Our analyses of these signatures are contained in Supplementary File 2
[Baggerly and Coombes (2009b)].
4. Case study 3: Combination therapy. We next examined the approaches
used to investigate combination therapy. Potti et al. (2006) mention success
in deriving predictions for breast cancer patients treated with a combina-
tion of paclitaxel (taxol), 5-fluorouracil, adriamycin and cyclophosphamide
(TFAC). Their methods note that the combination predictions were de-
rived from those for the individual drugs using “the theorem for combined
probabilities as described by William Feller.” Later, Bonnefoi et al. (2007)
provided a “validation” of the combination approach, using it to predict
patient response to two alternative therapies: taxotere (docetaxel) followed
by epirubicin (similar to doxorubicin) and taxotere (TET), and fluorouracil,
epirubicin and cyclophosphamide (FEC). In terms of documentation and
reproducibility, our goals here are to clarify the combination rules and to
check predictions for the best single drug. We acquired raw CEL files and
array quantifications from GEO (GSE6861; posted quantifications have been
revised since we obtained them at the end of 2007). We obtained a missing
CEL file (HB131) and a table giving the individual and combination drug
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predictions from the statistical team in Lausanne which used the predictions
to construct ROC curves.
4.1. Treatment is confounded with run date. We first checked for gross
differences in the array data. Examining high pairwise correlations shows
the presence of three clear blocks [Figure 3(a)]. We then extracted run date
and lab information from the CEL file headers and plotted the data by run
date [Figure 3(b)]; the three clusters correspond to three major run blocks.
Different symbols in Figure 3(b) show that the first block contains half of the
patients treated with FEC, and that roughly half of the samples run at this
time were excluded from the final analysis. The second block contains the
second half of the patients treated with FEC. The third block contains all
of the patients treated with TET; all of these arrays were run on a different
scanner than those from the first two blocks. There is perfect confounding
of run date with treatment.
4.2. Three different combination rules were used. We then tried to iden-
tify the rules used to combine individual drug predictions into a combination
score. Letting P (·) indicate probability of sensitivity, the rules used are as
follows:
P (TFAC) = P (T ) +P (F ) +P (A) +P (C)−P (T )P (F )P (A)P (C),
P (TET ) = P (ET ) = max[P (E), P (T )],
and
P (FEC) = 5
8
[P (F ) + P (E) + P (C)]− 1
4
.
Values obtained with the first rule were all greater than 1, so the largest value
was set to 1, the smallest to 0, and the others fit by linear interpolation.
Values bigger than 1 or less than 0 using the third rule were set to 1 and
0, respectively. These rules are not explicitly stated in the methods; we
inferred them either from formulae embedded in Excel files (TFAC) or from
exploratory data analysis (TET and FEC). None of these rules are standard.
Since all three rules are different, it is not clear what rule was validated.
4.3. We can’t match the accuracy for the best drug/treatment combina-
tion [Figure 3( c)]. We also tried to roughly replicate the sensitivity pre-
dictions reported for the best performing component: cyclyophosphamide
in the FEC group. To do this, we first matched the X3P platform probe-
sets Bonnefoi et al. (2007) report for cyclophosphamide with the U95Av2
platform probesets now available as part of the supplementary information
for Potti et al. (2006). This was accomplished first by using “chip comparer”
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Fig. 3. Aspects of the Bonnefoi et al. (2007) study of combination therapy. ( a) Examin-
ing array quantifications for high pairwise correlations shows three blocks in the data. (b)
Plotting array run date by index shows the same three blocks. The first block contains half
of the patients treated with FEC; the other samples in this block were excluded. The second
block contains the other half of the patients treated with FEC. The third block contains all
of the patients treated with TET, with the arrays run on a different scanner. ( c) ROC
curves for the single best set of drug predictions: cyclophosphamide for FEC. The reported
curve has an AUC of 0.943, indicating extremely good prediction. Our best approximation
has an AUC of 0.348, indicating if anything performance worse than chance. (d) Drug
sensitivity data for pemetrexed, with the cell lines named for cyclophosphamide indicated.
The corresponding plot for cyclophosphamide itself is roughly flat. Pink triangles indicate
cell lines that were not reported but are required to generate the gene list reported.
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(http://chipcomparer.genome.duke.edu), which defined one-to-one map-
pings for most of the probesets, and using the platform annotation available
from either GEO or GeneCards to resolve any ambiguities. We then approx-
imated the binreg metagene (SVD) computation in R code, and produced
ROC curves using both the reported predictions and those we assembled
[Figure 3(c)]. The ROC curve assembled with the reported predictions (AUC
of 0.943) perfectly matches that given by Bonnefoi et al. (2007). Our own
curve (AUC of 0.348) is qualitatively different.
4.4. Sensitivity to cyclophosphamide doesn’t separate the cell lines used.
Sensitivity to pemetrexed does. We also examined the drug sensitivity data
for cyclophosphamide (NSC 26271) to clarify how the cell lines were chosen,
but saw no differential activity. This is driven by the fact that cyclophos-
phamide is a prodrug (a drug that needs to be processed by the body to
produce the active form), and has no direct effect on cell lines. The cell lines
used for cyclophosphamide match those found above in the signature for
pemetrexed; sensitivity data for pemetrexed is shown in Figure 3(d).
4.5. Summary. Design confounding was not mentioned. Poor documen-
tation obscured the fact that different combination rules were used, and
leaves both the computation of scores and selection of cell lines for cyclophos-
phamide unclear. Details of our analyses are given in Supplementary File 3
[Baggerly and Coombes (2009c)].
5. Case study 4: Temozolomide. We next examined the signature for
temozolomide reported by Augustine et al. (2009), who discuss how it might
be useful for predicting response in melanoma. The initial signature involved
45 genes separating 9 resistant from 6 sensitive cell lines, with cell lines com-
ing from the NCI-60 panel. In terms of documentation and reproducibility,
our goal here is to match the results to the drug named. We acquired the
heatmap from Augustine et al. (2009)’s Figure 4A and the genes from their
supplementary table.
5.1. The gene list doesn’t match the heatmap. We first tried to confirm
the behavior of the individual genes. The gene list indicates that 8 probesets
are more strongly expressed in the resistant lines, with the other 37 more
strongly expressed in the sensitive lines. However, three genes (RRAGD,
SFN and SLC43A3) are listed as higher in both groups (these genes were
interrogated by multiple probesets).
5.2. The heatmap is that published for cisplatin (Figure 4). We tried to
match the heatmap reported following the approach described above for cis-
platin, but were unsuccessful. We then visually compared the temozolomide
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(a) (b)
Fig. 4. Approximations to ( a) the heatmap initially presented in Figure 4A of Augustine
et al. (2009) for temozolomide, with lines reportedly chosen from the NCI-60 cell line panel,
and (b) the heatmap presented in Figure 1 of Hsu et al. (2007) for cisplatin, with cell lines
chosen from the 30-line panel of Gyo¨rffy et al. (2006). The heatmaps are the same. We
have independently generated the cisplatin heatmap using the Gyo¨rffy et al. (2006) data,
but the temozolomide heatmap is neither for temozolomide nor from the NCI-60 panel.
and cisplatin heatmaps (approximated in Figure 4). The heatmaps are iden-
tical. Since we independently regenerated the cisplatin heatmap using cell
lines from Gyo¨rffy et al. (2006), this heatmap does not correspond to temo-
zolomide and was not derived from the NCI-60 cell lines. Since the reported
gene list does not match the list for cisplatin (even allowing for offsetting),
we presumed that it should correspond to the true list for temozolomide.
5.3. Journal communication led to a new heatmap with different prob-
lems. In correction, a new figure was supplied [Augustine et al. (2009)].
The corrected heatmap involves 150 genes, not 45, so the initial gene list
evidently matches neither cisplatin or temzolomide. The revised heatmap
shows 5 resistant lines, 5 sensitive lines and 150 probesets, as opposed to 9,
6 and 45 before. The fraction of probesets higher in the resistant group has
changed from 8/45 to about 110/150. As noted in the Introduction, the ini-
tial heatmap was described in detail in the text of Augustine et al. (2009),
but none of these differences were noted. The new caption names 93 genes
as higher in the resistant group. Visual inspection shows about 110.
5.4. Summary. Poor documentation led a report on drug A to include a
heatmap for drug B and a gene list for drug C. These results are based on
simple visual inspection and counting, and are not documented further.
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6. Case study 5: Surveying cell lines used. In light of the above issues,
we decided to assemble a more extensive overview of which cell lines were
treated as sensitive or resistant for various drugs. We considered 12 sources of
information about the signatures for 10 drugs: docetaxel (D), paclitaxel (P),
doxorubicin (adriamycin, A), fluorouracil (F), topotecan (T), etoposide (E),
cyclophosphamide (C), pemetrexed (Pem), cisplatin (Cis) and temozolomide
(Tem). The sources are as follows:
1. Heatmaps from Potti et al. (2006) (D, P, A, F, T, E), November 2006.
2. Heatmaps from Hsu et al. (2007) (Cis, Pem), October 2007.
3. Gene lists from Potti and Nevins (2007) (D, P, A, F, T, E, C), November
2007.*
4. Docetaxel quantifications from the Potti et al. (2006) website (D), Novem-
ber 2007.
5. Doxorubicin quantifications from the Potti et al. (2006) website (A),
November 2007.
6. The “list of cell lines used” and the “description of predictor generation”
from the Potti et al. (2006) website (D, P, A, F, T, E, C), November
2007.*
7. The “list of cell lines used” supplied as a webpanel supplement to
Bonnefoi et al. (2007) (D, A, F, C), December 2007.
8. Numbers of sensitive and resistant lines used by Salter et al. (2008) (P,
A, F, C), April 2008.*
9. The “list of cell lines used” posted on the Potti et al. (2006) website (D,
P, A, F, T, E, C), August 2008.
10. The “list of cell lines used” by Bonnefoi et al. (2007) after correction
(D, A, F, C), September 2008.
11. Numbers of sensitive and resistant lines named by Riedel et al. (2008)
(D, P, A, F, T, E, C), October 2008.*
12. Heatmap from Augustine et al. (2009) (Tem), January 2009.
We draw inferences from heatmaps and gene lists when we are able to exactly
match the reported results with the binreg software used by Potti et al.
(2006). This uniquely identifies the two groups being contrasted, but not the
direction (which group is sensitive). Direction is inferred from other state-
ments in the relevant papers about what the figures represent. In some cases
(*’s above) either the direction or the identity of the cell lines is not precisely
specified, so some information must be inferred from other sources. These
“other sources” need not be complex; in the case of Salter et al. (2008), for
example, we simply examined the heatmaps and counted the numbers of cell
lines on the left and right of the major divide.
6.1. Sensitive/resistant label reversal is common (Figure 5). The cell line
lists and information sources are summarized in Figure 5. Color changes
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Fig. 5. Mapping of which NCI-60 cell lines were used as sensitive or resistant for which
drugs, and the information source used for the inference. For example, there are 8 sources
of information (columns) for docetaxel; in column 3, corresponding to the docetaxel quan-
tifications supplied in November 2007, cell line NCI-H522 was listed as resistant. All
drug groupings with more than one column show color flips, corresponding to reversal
of the sensitive/resistant labeling. Cell lines are different for most drugs save cyclophos-
phamide/pemetrexed. No cell lines are indicated for cisplatin or temozolomide; the first
signature was derived from a different set of cell lines, and in the heatmap reported for
temozolomide is actually the heatmap for cisplatin.
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across rows show that there is at least one sensitive/resistant label reversal
for every drug checked more than once. The sets of cell lines are different
for most drugs, with the exception of cyclophosphamide/pemetrexed noted
above. The cell lines reported for cyclophosphamide are a subset of those
used for pemetrexed, but running the cyclophosphamide cell lines through
binreg does not produce the gene list reported. The cell lines producing
the cyclophosphamide gene list are a superset of those used for pemetrexed.
The cisplatin signature is based on 30 cell lines assembled by Gyo¨rffy et al.
(2006); the heatmap reported for temozolomide matches that for cisplatin.
Based on the drug sensitivity information, we believe the orientations
given in the August 2008 lists of cell lines (Potti Corr 2 list) are correct. As-
suming this is the case, Figure 5 shows the sensitive/resistant orientations of
the Salter et al. (2008) heatmaps are correct for T and A but incorrect for F
and C. Heatmap orientations in Potti et al. (2006) are reversed for T, A and
F, and we cannot reproduce the heatmap for C. However, sample predictions
shown in both Figure 3A of Potti et al. (2006) and Figure 2B of Salter et al.
(2008) suggest results better than even for all four drugs [Potti et al. (2006)
p-values: T = 0.002, F = 0.3, A = 0.024, C = 0.003; Salter et al. (2008) p-
values: T = 0.07, F = 0.02, A = 0.01, C = 0.02].
6.2. Summary. Poor documentation hides the fact that sensitive and re-
sistant labels are being used inconsistently over time, even though this direc-
tion determines whether the drug should be offered or withheld. Full details
of the figure assembly are given in Supplementary File 4 [Baggerly and Coombes
(2009d)].
7. Discussion.
7.1. On the nature of common errors. In all of the case studies exam-
ined above, forensic reconstruction identifies errors that are hidden by poor
documentation. Unfortunately, these case studies are illustrative, not ex-
haustive; further problems similar to the ones detailed above are described
in the supplementary reports. The case studies also share other common-
alities. In particular, they illustrate that the most common problems are
simple: for example, confounding in the experimental design (all TET be-
fore all FEC), mixing up the gene labels (off-by-one errors), and mixing up
the group labels (sensitive/resistant); most of these mixups involve simple
switches or offsets. These mistakes are easy to make, particularly if work-
ing with Excel or if working with 0/1 labels instead of names (as with
binreg). We have encountered these and like problems before. As part
of the 2002 Competitive Analysis of Microarray Data (CAMDA) compe-
tition, Stivers et al. (2003) identified and corrected a mixup in annotation
affecting roughly a third of the data which was driven by a simple one-cell
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deletion from an Excel file coupled with an inappropriate shifting up of all
values in the affected column only. Baggerly, Morris and Coombes (2004),
Baggerly et al. (2004) and Baggerly et al. (2005) describe cases of complete
confounding leading to optimistic predictions for proteomic experiments.
Baggerly, Coombes and Neeley (2008) describe another array study where
there was a mixup in attaching sample labels to columns of quantifications,
most likely driven by omission of 3 CEL files leading to an off-by-three error
affecting most of the names. These experiences and others make us worry
about the dual of the italicized statement above, that the most simple prob-
lems may be common.
7.2. On the hiding of simplicity. While simple mistakes often allow for
simple fixes, incomplete documentation and lack of reproducibility means
that this simplicity is often hidden. Further, it means that identifying the
problems often requires going across several sources of information, papers
and journals, making simple fixes difficult. Identifying the training data
cell lines in Adria ALL.txt used the fact that they were in the same order
as in the Potti et al. (2006) heatmaps for correlation matching. Identifying
cell lines for cisplatin used knowledge of the possibility of an off-by-one
error. Identifying the overlap of the cell lines used for cyclophosphamide
and pemetrexed required identifying the cell lines and comparing lists across
papers. Identifying the initial heatmap for temozolomide required familiarity
with the one for cisplatin. This cascade can lead to a certain archaeology
with respect to what has been established “as previously shown.” This can
also render some conclusions unfalsifiable, for example, with the rejoinder
“they get our results when they use our methods” provided without details
[Potti and Nevins (2007); see Supplementary File 5, Baggerly and Coombes
(2009e)].
7.3. What should be done. So, what can be done? We address this ques-
tion in two parts: with respect to the specific findings illustrated here, and
with respect to reproducibility in general.
7.3.1. In the case of these results. In the case of these results, we don’t
think the approach works. We think stronger evidence (including worked
examples of how it works) need to be provided before this approach is used to
guide patient allocation in clinical trials. In the case of the clinical trial noted
above, assuming the general approach works means that sensitive/resistant
label reversal for one of the drugs (pemetrexed) may actually put patients
at risk by giving guidance at odds with the truth, whereas assuming the
general approach doesn’t work means that little will be learned from the
trial or even that it may provide misleading support for the approach given
the inclusion of genes that shouldn’t be there (ERCC1, ERCC4).
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A broader question is whether this approach could work if applied cor-
rectly. We don’t think so. We have tried making predictions from the NCI60
cell lines when we step through the process without the errors noted above,
and we get results no better than chance. We communicated with the authors
extensively in the early phases of our investigation (which we recommend),
and shared the fact that we didn’t think it worked before submitting our
initial note [Coombes, Wang and Baggerly (2007)]. Empirically, however, we
have reached an impasse, as the progression to clinical trials attests.
7.3.2. In the case of reproducibility in general. In the case of repro-
ducibility in general, journals and funding agencies already require that raw
data (e.g., CEL files) be made available. We see it as unavoidable that com-
plete scripts will also eventually be required. General guidelines outlining
the types of questions authors should be prepared to answer in detail are
discussed in the REporting recommendations for tumor MARKer prognostic
studies (REMARK) guidelines [McShane et al. (2005)].
7.4. What we’re doing. Partially in response to the examples discussed
here, we instituted new operating procedures within our group, mostly sim-
ple things having to do with report structure. Reports in our group are typ-
ically produced by teams of statistical analysts and faculty members, and
issued to our biological collaborators. We now require most of our reports
to be written using Sweave [Leisch (2002)], a literate programming com-
bination of LATEX source and R [R Development Core Team (2008)] code
(SASweave and odfWeave are also available) so that we can rerun the re-
ports as needed and get the same results. Some typical reports are shown
in the supplementary material. Most of these reports are written by the
statistical analysts, and read over (and in some cases rerun) by the faculty
members. All reports include an explicit call to sessionInfo to list libraries
and versions used in the analysis. The working directory and the location of
the raw data are also explicitly specified (in some cases leading to raw data
being moved from personal machines to shared drives). We also check for the
most common types of errors, which are frequently introduced by some sev-
ering of data from its associated annotation [e.g., using 0 or 1 for sensitive or
resistant instead of using names (noted above), supplying one matrix of data
and another of annotation without an explicit joining feature, calls to order
one column of a set]. R’s ability to let us use row and column labels which
it maintains through various data transformations helps. These steps have
improved reproducibility markedly. We have also assumed a fairly regular
report structure in order to enhance clarity, including an executive sum-
mary (at most two pages of text) detailing Background, Methods, Results
and Conclusions in the format most familiar to our biological collaborators.
Discussing the Background and Methods with the collaborators ahead of
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time helps ensure we’re working on the problems of actual interest. Finally,
we are trying to shift more frequently to the use of standardized templates
for common analyses (e.g., two group comparisons for microarray studies).
There is definitely a startup cost in time when shifting to this approach, but
this is often made up when we have to modify earlier analyses months or
years later.
7.5. The bottom line. While it may be difficult, we think the examples
above show that this added layer of documentation is required for high-
throughput biology.
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SUPPLEMENTARY MATERIAL
Supplement A: Examining doxorubicin in detail
(DOI: 10.1214/09-AOAS291SUPPA; .zip). Zipped pdf report describing the
identification of ties and sensitive/resistant status for samples checked for
doxorubicin.
Supplement B: Cisplatin and pemetrexed (DOI: 10.1214/09-AOAS291SUPPB;
.zip). Zip file containing two pdf reports, matchingCisplatinHeatmap and
matchingPemetrexedHeatmap, describing the matching of the respective
heatmaps together with sample and gene identification.
Supplement C: Examining combination therapy
(DOI: 10.1214/09-AOAS291SUPPC; .zip). Zip file containing seven pdf re-
ports: getTestingNumbers, getTestingClinical (for identification of blocks
and confounding), checkOldCombinationRule, checkDrugSensitivity (for the
combination rules), mapGeneLists and predictCytoxanSensitivity (for the
ROC curves), and checkingCellLines (for the drug sensitivity values).
Supplement D: Surveying cell lines (DOI: 10.1214/09-AOAS291SUPPD;
.zip). Zip file containing two pdf reports: enumeratingCellLines, describing
assembly of the figure, and getTrainingCellLines from the study of combi-
nation therapy, for identification of the cell lines needed to produce the gene
list for cyclophosphamide.
Supplement E: Examining docetaxel in detail
(DOI: 10.1214/09-AOAS291SUPPE; .zip). Zipped pdf report describing the
identification of ties and sensitive/resistant status for samples checked for
docetaxel.
All reports are in Sweave. More reports, data and code, are at
http://bioinformatics.mdanderson.org/Supplements/ReproRsch-All. Reports
concerning combination therapy are at ReproRsch-Breast.
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